Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017097407) AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-1 ANTIBODY AVELUMAB
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/097407 International Application No.: PCT/EP2016/002040
Publication Date: 15.06.2017 International Filing Date: 05.12.2016
IPC:
A61K 39/395 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250 64293 Darmstadt, DE
PFIZER, INC. [US/US]; 235 East 42nd Street New York, New York 10017, US
Inventors:
RINALDI, Gianluca; IT
DEL RIO, Alessandra; IT
FRATARCANGELI, Silvia; IT
VOSS, Senta; DE
WEIGANDT, Markus; DE
Priority Data:
15198233.707.12.2015EP
Title (EN) AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-1 ANTIBODY AVELUMAB
(FR) FORMULATION PHARMACEUTIQUE AQUEUSE COMPRENANT UN ANTICORPS ANTI-PD-1, L'AVELUMAB
Abstract:
(EN) The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
(FR) La présente invention concerne une nouvelle formulation d'anticorps anti-PD-L1. En particulier, l'invention concerne une formulation pharmaceutique aqueuse de l'anticorps anti-PD-L1, l'Avelumab.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
UAa201807363AR107014CA3007481AU2016368099MYPI 2018702171IL259563
SG11201804758QKR1020180085801CN108367072IN201817018822EP3386541ID2018/11189
PH1/2018/500894US20180369377EA201891339BR112018010211